We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00380302
Recruitment Status : Completed
First Posted : September 25, 2006
Last Update Posted : December 19, 2008
Information provided by:

Brief Summary:

Primary: This study is being conducted to evaluate if AVE1625 is safe and tolerated in patients with Alzheimer's disease that is not too severe. There is also evaluation of whether patients who take the study medication improve compared to patients who take a placebo (sugar pill).

Secondary:The study will also evaluate the blood levels of the study medication, AVE1625 in patients who join the study.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Drug: AVE1625 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 162 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind Placebo-Controlled Study of the Activity of AVE1625 at Doses of 10 mg and 40mg for 12 Weeks in Patients With Mild to Moderate Alzheimer's Disease
Study Start Date : September 2006
Actual Primary Completion Date : July 2007
Actual Study Completion Date : July 2007

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Safety and tolerability throughout the study:adverse events collected by spontaneous report
  2. physical examination and neurological assessment
  3. vital sign monitoring, clinical laboratories, and ECGs.
  4. Efficacy variables:measures of change in cognition, global functioning and behavior at week 12.

Secondary Outcome Measures :
  1. Pharmacokinetic parameters will be assessed throughout the 12-week treatment period.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The diagnosis of Alzheimer's disease
  • Recent brain image(Computerized Axial Tomographic Scan -CAT scan or Magnetic Resonance Imaging - MRI)
  • Mild to moderate range of disease; not too severe

Exclusion Criteria:

  • Severe or unstable medical diseases
  • Neurological disorder other than Alzheimer's disease
  • Depression that is not well controlled
  • Treatment with memantine
  • Inpatient in a total care facility (e.g.: Nursing home)
  • Lack of reliable caregiver

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00380302

Layout table for location information
United States, New Jersey
Sanofi-Aventis Administrative Office
Bridgewater, New Jersey, United States, 08807
Sanofi-Aventis Administrative Office
Paris, France
Sanofi-Aventis Administrative Office
Milano, Italy
Sanofi-Aventis Administrative Office
Gouda, Netherlands
Sanofi-Aventis Administrative Office
Bromma, Sweden
Sponsors and Collaborators
Layout table for investigator information
Study Director: ICD CSD Sanofi
Additional Information:
Layout table for additonal information
Responsible Party: ICD Study Director, sanofi-aventis
ClinicalTrials.gov Identifier: NCT00380302    
Other Study ID Numbers: ACT10019
EUDRACT: 2006-002317-12
First Posted: September 25, 2006    Key Record Dates
Last Update Posted: December 19, 2008
Last Verified: December 2008
Keywords provided by Sanofi:
Alzheimer's disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders